Structure Therapeutics (NASDAQ:GPCR) shared new top-line results from its ACCESS II clinical program for aleniglipron, an ...
We recently published 10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs. Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the best performers on Monday. Structure Therapeutics soared to ...
Structure Therapeutics IncGPCR shares are up on Wednesday, probably in reaction to the U.S. Food and Drug Administration (FDA ...
Meridian Funds, managed by ArrowMark Partners, released its fourth-quarter 2025 investor letter for “Meridian Small Cap Growth Fund”. A copy of the letter can be downloaded here. U.S. equity markets ...
Novo Nordisk NVO and Structure Therapeutics GPCR have emerged as noteworthy companies in the obesity space. A market leader ...
Stocktwits on MSN
VKTX vs. GPCR: Which obesity drug developer does Wall Street see with the bigger upside?
Earlier this month, Viking announced competition for patient enrollment in its late-stage clinical trial of subcutaneous ...
GLP-1 agonist drugs like Novo Nordisk's semaglutide and Eli Lilly's tirzepatide are set to become all-time best-selling drugs. Structure Therapeutics has entered the race with an oral GLP-1 candidate, ...
Fintel reports that on December 11, 2025, Jefferies maintained coverage of Structure Therapeutics Inc. - Depositary Receipt (NasdaqGM:GPCR) with a Buy recommendation. As of December 6, 2025, the ...
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...
Pfizer is one of several drugmakers working to develop an alternative to injectable weight loss drugs. Still, it’s far behind rivals like Eli Lilly and Novo Nordisk, who already lead the market with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results